BIO calls for withdrawal of OMB grant rule, PhRMA wants changes

CEOs of the pharmaceutical and large biotech companies, including those who have relationships with President Donald Trump, have not chosen to publicly address the Trump administration’s proposals to exert political control over federal grantmaking. The industry has, however, submitted formal comments through its two most prominent trade associations.

In addition, No Patient Left Behind (NPLB), an advocacy group founded and backed by RA Capital Managing Partner Peter Kolchinsky, has submitted a letter signed by more than 180 investors, leaders of emerging biotech companies, and academic researchers. ...